Evidence map›Paper›PMID 28289899›Full record

ArticleJournal of cancer research and clinical oncology2017

Role of BMI and hormone therapy in melanoma risk: a case-control study.

Vincenzo De Giorgi, Alessia Gori, Imma Savarese, Antonietta D'Errico, Federica Scarfì, Federica Papi, Vincenza Maio, Piero Covarelli, Daniela Massi, Sara Gandini

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. A Narrative Review of the Role of Estrogen (Receptors) in Melanoma.International journal of molecular sciences · 2024
    Review
  3. Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma.American journal of physiology. Endocrinology and metabolism · 2024
    Article
  4. Article
  5. Daily Lifestyle and Cutaneous Malignancies.International journal of molecular sciences · 2021
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Vincenzo De GiorgiDepartment of Dermatology, University of Florence, Via Michelangelo 41, 50124, Florence, Italy. vincenzo.degiorgi@unifi.it.
Alessia GoriCancer Research "Attilia Pofferi" Foundation, Pistoia, Italy.
Imma SavareseDepartment of Dermatology, University of Florence, Via Michelangelo 41, 50124, Florence, Italy.
Antonietta D'ErricoDepartment of Dermatology, University of Florence, Via Michelangelo 41, 50124, Florence, Italy.
Federica ScarfìDepartment of Dermatology, University of Florence, Via Michelangelo 41, 50124, Florence, Italy.
Federica PapiDepartment of Dermatology, University of Florence, Via Michelangelo 41, 50124, Florence, Italy.
Vincenza MaioDepartment of Human Pathology and Oncology, University of Florence, Florence, Italy.
Piero CovarelliDepartment of Dermatology, University of Perugia, Perugia, Italy.
Daniela MassiDepartment of Human Pathology and Oncology, University of Florence, Florence, Italy.
Sara GandiniDivision of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
University of Florence · ITEuropean Institute of Oncology · ITUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, the association between body mass index (BMI) and hormone therapies and Cutaneous Melanoma (CM) development is strongly debated. This study was carried out to assess the association between BMI, hormone therapies, and CM risk.

methodsThe present study is a hospital-based case-control study with 605 consecutive CM patients and 592 controls treated for non-neoplastic conditions at the Department of Dermatology in Florence. The associations of melanoma risk with BMI and hormone therapies were assessed performing unconditional logistic regression to estimate odds ratios (OR) and their 95% confidence intervals, adjusting for potential confounders.

resultsWe found a significant interaction of BMI with age (P < 0.0001): being overweight significantly increased CM risk among individuals less than 50 years old (OR = 1.85 with 95% CI 1.14-2.94), whereas the association was not significant for individuals over 50 years old (OR = 1.15 with 95% CI 0.77-1.71). For oestrogen therapy, women taking oral contraceptives (OCs)/hormone replacement therapy (HRT) showed a lower CM risk than men (OR = 0.63, 95% CI 0.44-0.89), with risk estimates significantly lower (P < 0.0001) than in non OCs/HRT users, which had an increased risk compared to men (OR = 1.81, 95% CI 1.29-2.53).

conclusionsBeing overweight was significantly associated with CM risk, and this relationship was highly age-conditioned; the second finding was the protective effect of oestrogen therapies for women. Both findings may have a significant impact on melanoma prevention, as the prevalence of obesity and hormone therapy use is increasing worldwide.

Indexed as

Hormone Replacement TherapyAdultAgedBody Mass IndexCase-Control StudiesCutaneous Malignant MelanomaFemaleHumansMaleMelanomaMiddle AgedOdds RatioOverweightPrevalenceRisk FactorsSkin NeoplasmsAgeBody mass indexCutaneous melanomaHormone therapiesOverweight status

Identifiers

PMID28289899
PMCPMC11819055
OpenAlexW2595071814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.